Trial Profile

A Phase Ib Safety, Pharmacokinetics and Pharmacodynamics Study of TU7710 in Patients with Haemophilia A or B

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NBP 604 (Primary)
Indications Haemophilia A; Haemophilia B
Focus Adverse reactions
Sponsors TiumBio

Most Recent Events

19 Sep 2025 This trial has been discontinued in Romania (Sponsor Decision), according to Clinical Trials Information System.
28 Mar 2024 New trial record
26 Mar 2024 According to a TiumBio media release, the company has filed a Clinical Trial Application (CTA) with the Italian Medicines Agency (AIFA) and the Spanish Agency of Medicines and Medical Products (AEMPS) to initiate a Phase 1b study with the TU7710. The trial will enroll up to 18 hemophilia A or B patients with inhibitors and will be conducted in Italy and Spain.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com